SUMMARY In a retrospective study pancreatic juice samples (n=213) and corresponding serum samples (n=110) were assayed for their concentration of monoclonal antibody defined CA 19-9/ GICA (gastrointestinal cancer associated antigen). Serum CA 19-9 values were found to be good diagnostic and discriminating markers for pancreatic disorders and were raised (>50 u/ml) in more than 80% of the pancreatic cancer patients compared to 8 5% of the pancreatitis group and none of the control group. In contrast pancreatic juice CA 19-9 values showed a considerable overlap between groups. On the basis of recent molecular data on the monoclonal antibody 19-9 defined antigen(s) -that is, monosialoganglioside, mucin -it is proposed that the discrepancies between serum and pancreatic juice findings are due to a specific undirected endocrine release of the mucin into sera in pancreatic tumour patients while in pancreatic juices of all diagnostic groups high CA 19-9 activities are either owing to coexistence of glycolipid and mucin or that the latter is a physiologically exocrine product.
By means of hybridoma technology a radioimmunometric assay has been recently developed and first radio-immunometric quantitations of a carbohydrate determinant [(a sialylated lacto Nfucopentaose II)8] by monoclonal antibody 19-99" in sera of patients suffering from GI-tract cancer have revealed a high specificity (98.5%) and sensitivity (79%) for pancreatic cancer.12 In this retrospective study we hand 31% of the pancreatic cancer patients (1) compared to 12*7% of the pancreatitis group (2) and 12% of the controls (3) showed pancreatic juice CA 19-9 concentrations of more than 104 U/ml. Corresponding serum CA 19-9 results were available in 110 patients (Table) . Significantly (p<001, Kruskal-Wallis-Test) raised levels of CA 19-9 (>37 U/ml) were found in the pancreatic cancer group (1) . In contrast, the other groups and especially that of pancreatitis patients showed lower values (Fig. 2) . When taking cutoff values of 37 U/ml 85% of the pancreatic cancer patients (1) but only 14% of the pancreatitis patients and 15% of the control group showed scores beyond this. By raising the cutoff value to 50 U/ml the discrimination between the pancreatic cancer group (81% >50 U/ml) and group 2 (8-5% >50 U/ml) and group 3 (0 >50 U/ml), respectively, could be improved.
Taking into account that the amount of a tumour marker secreted or shed by tumour cells will also depend on the tumour mass we tried to correlate CA 19-9 scores with pancreatic tumour staging. For this purpose CA 19-9 values obtained from pancreatic juice (n=63) or serum analyses (n=41) were related to TNM classification'4 of the corresponding patients. As outlined in Fig. 3 
